Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs

BACKGROUND: Canine heartworm (Dirofilaria immitis), a filarial parasite endemic in many countries worldwide, can cause life-threatening disease in dogs if left untreated. Two laboratory studies and one field study were conducted to evaluate the efficacy of Credelio Quattro, a novel chewable tablet containing moxidectin in combination with lotilaner, praziquantel and pyrantel, for the prevention of heartworm disease caused by D. immitis. METHODS: (moxidectin/sarolaner/pyrantel), at the recommended label dosages for 11 consecutive months. Efficacy was evaluated on Day 330 by assessing the detection of adult heartworm infections using antigen and microfilarial tests. RESULTS: In both laboratory studies, no adult heartworms were collected from any of the dogs treated with a single dose of Credelio Quattro. In contrast, all dogs treated with placebo (range 13-40) or lotilaner-only (range 9-42) had adults present. A total of 372 dogs were enrolled in the field study (191 Credelio Quattro, 181 Simparica Trio). At the end of the study, no dogs from either treatment group tested positive for adult heartworms. Credelio Quattro was well tolerated in all studies. CONCLUSIONS: The laboratory studies demonstrated Credelio Quattro as 100% effective for the prevention of heartworm disease caused by D. immitis in dogs. Additionally, no dogs in the field study tested positive for adult heartworm infection after 11 consecutive monthly doses of Credelio Quattro.